Pulse Biosciences co-chairmen buy $13.3 million in company stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million
May 12, 2026 7:00 AM EDTHAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse technology using proprietary nanosecond pulsed field ablation (nsPFA) energy, today announced its Co-Chairmen of the Board, Robert Duggan and Chief Executive Officer Paul LaViolette, completed purchases of Pulse Biosciences common stock through its at-the-market equity offering program (ATM) during the Companys designated... More
